Heat Biologics' Lead Candidate Shows Overall Survival Benefit In Lung Cancer Study

Heat Biologics Inc HTBX has reported interim data from the Phase 1/2 trial evaluating its lead product, HS-110, in combination with Bristol-Myers Squibb Co's BMY Opdivo (nivolumab) in advanced non-small-cell lung cancer (NSCLC) patients.
The data will be presented at the 2021 American Society of Clinical Oncology Annual Meeting.
Median progression-free survival (PFS) in cohort A (n=47) was 1.8 months, and median overall survival (OS) was 24.6 months.
Significantly longer PFS and OS in injection site reaction+ patients were observed and longer OS in PD-L1+ patients.
In cohort B (n=68), median PFS was 2.8 months, and median OS was 11.9 months.
A trend toward extended OS in blood tumor mutational burden with less than ten mutations was seen.
Treatment-emergent adverse reactions were reported in 21 (44.7%) patients in cohort A and 18 (26.5%) patients in cohort B.
Few HS-110–related adverse reactions led to discontinuation of treatment (cohort A, 5 (10.6%); cohort B, 3 (4.4%), and no serious adverse events were considered related to HS-110.
Price Action: HTBX shares are up 4.5% at $6.50 on the last check Thursday.